Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch

Helen Parfitt has joined Research Partnership as Head of Therapy Watch at the company’s global head office in London. Therapy Watch is a ‘real-time’ syndicated global market tracking tool that provides the pharmaceutical industry with strategic and tactical market information on their brands.

Helen has over 20 years’ experience in the pharmaceutical industry and joins Therapy Watch from the M3 Group where she was a Commercial Director for their European division. Prior to this she was Director of Core Data Assets, Global Technology Services & Operations at IMS Health, where she led the global syndicated data portfolio.  Helen brings with her extensive and wide ranging pharmaceutical and management experience including roles at GlaxoSmithKline and Schering-Plough where she was a Product Manager.

Helen joins Research Directors Julia Godfrey and Laurent Chanroux in supporting the continued expansion of Therapy Watch, which currently runs global monitors in auto-immune, virology, oncology and nephrology and recently expanded its oncology portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Chronic Myeloid Leukaemia (CML) in 2017. 

Commenting on her appointment Mark Jeffery, Founding Director, said, “We are delighted to welcome Helen to Research Partnership. Helen brings with her a wealth of knowledge and expertise. Her experience at GSK and Schering- Plough means she has also developed a strong understanding of clients’ needs.  I believe she will be a strong asset to the Therapy Watch team and we look forward to her contributing to its continued growth and development.”

To find out more about Therapy Watch please visit researchpartnership.com/therapywatch